The Bringing Chemistry to Medicine symposium features thought leaders at the interface of chemical and biomedical sciences, working in areas spanning therapeutic regulation of transcription and chromatin, computational biology, and chemical biology. This year’s annual symposium features two themes: Transcription Therapy (Thursday, July 22) and Frontiers in Chemical Biology (Friday, July 23).
This virtual symposium, hosted by the St. Jude Department of Chemical Biology and Therapeutics and the St. Jude Comprehensive Cancer Center, is a component of the institution’s strategic objective to establish a global hub focused on the emerging field of transcription-targeted therapeutics.
To enable broad participation and interaction among trainees and scientists around the world, registration is free.
M. Madan Babu
St. Jude Children's Research Hospital
Suzanne J. Baker
St. Jude Children's Research Hospital
James E. Bradner
Novartis Institutes for Biomedical Research
Andrea Califano
Columbia University
Francesca Ciccarelli
The Francis Crick Institute
Patrick Cramer
Max Planck Institute
Craig Crews
Yale University
Pedro R. Cutillas
Cancer Research UK Barts Center
Cigall Kadoch
Dana-Farber Cancer Institute, Harvard Medical School, and the Broad Institute of MIT and Harvard
William G. Kaelin, Jr
Dana-Farber Cancer Institute
Mitch Lazar
University of Pennsylvania
Jonathan Licht
University of Florida Health Cancer Center
Craig W. Lindsley
Vanderbilt University
Debora S. Marks
Broad Institute of MIT and Harvard, Harvard Medical School
Marvin J. Miller
University of Notre Dame
Anjana Rao
La Jolla Institute for Immunology
Tobin Sosnick
The University of Chicago
Janet Thornton
The European Bioinformatics Institute
Thursday, July 22: Transcription Therapy
Agenda events and times are currently being planned. Please check back for scheduling developments.
Friday, July 23: Frontiers in Chemical Biology
Agenda events and times are currently being planned. Please check back for scheduling developments.
Watch our Archived Lectures
In 2020, St. Jude hosted an exciting two-day event focused on Transcription Therapy and Chemical Biology and Therapeutics.
Transcription Therapy at St. Jude
Over decades of research, scientists in the St. Jude Comprehensive Cancer Center and others have discovered that several pediatric cancers emerge due to disruption in chromatin and epigenetic states and dysfunctional transcriptional regulation. While gene regulation in general has long been considered “undruggable,” scientists in the St. Jude Department of Chemical Biology & Therapeutics (CBT) have created synthetic gene regulators and are devising new chemical approaches to inhibit or degrade malfunctioning components of chromatin and gene regulatory machineries. This work builds on the history of St. Jude as a pioneer in the therapeutic use of small molecules targeting gene regulation, most notably the application of glucocorticoid receptor agonists into chemotherapy regimens for pediatric patients with acute lymphoblastic lymphoma (ALL). The drugging of this transcription factor helped to dramatically increase overall survival rates for newly diagnosed ALL to 94% at St. Jude.
Learn more about transcription therapy at St. Jude Learn more